Keyword: George Yancopoulos
Regeneron’s flagship med Eylea fell short of sales expectations in Q1, raising questions as Praluent idles and potential big-earner Dupixent makes its debut.
Regeneron CEO Len Schleifer has been at or near the top of the biopharma executive-pay charts for years. That’s still the case for 2016, but not by as wide a margin.
Allergan CEO Brent Saunders recently told investors that his company isn’t looking for any more “transformational” M&A. But on the chance a merger does put him out of a job? A mammoth goodbye present awaits.
Once again, Regeneron CEO Leonard Schleifer and his R&D chief George Yancopoulos are among the highest-paid executives in the industry, with $47.5 million and $40.3 in 2015 compensation.